Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel...

FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population Washington, DC, March 14, 2024 (GLOBE NEWSWIRE) -- Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication...

A Call for Help from Physician Specialists on the Frontline Treating MASLD/MASH Exton, Pennsylvania, July 18, 2023 (GLOBE NEWSWIRE) -- Data from the Centers for Disease Control & Prevention (CDC) suggests just over seventy percent of American adults are overweight,...